Projections of Healthcare Resource Utilization and Costs Related to Exacerbations for Budesonide/Glycopyrrolate/Formoterol Fumarate Versus Dual Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist and Inhaled Corticosteroid/Long-Acting β2-Agonist Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease

被引：0
|
作者：
De Nigris, E. [1 ]
Treharne, C. [2 ]
Brighton, N. [2 ]
Holmgren, U. [3 ]
Walker, A. [4 ]
Haughney, J. [5 ]
机构：
[1] AstraZeneca, Cambridge, England
[2] Parexel Int, London, England
[3] AstraZeneca, Gothenburg, Sweden
[4] Salus Alba, Glasgow, Lanark, Scotland
[5] Queen Elizabeth Univ Hosp, Clin Res Facil, Glasgow, Lanark, Scotland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2249
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting β2-agonist (LABA/LAMA) in the UK
    Requena, Gema
    Banks, Victoria
    Czira, Alexandrosz
    Wood, Robert
    Tritton, Theo
    Ha, Eunmi
    Wild, Rosie
    Compton, Chris
    Ismaila, Afisi
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [22] Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis
    Oba, Yuji
    Chandran, Arul V.
    Devasahayam, Joe V.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 13 (06) : 677 - 685
  • [23] Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single- Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
    Requena, Gema
    Banks, Victoria
    Czira, Alexandrosz
    Wood, Robert
    Tritton, Theo
    Wild, Rosie
    Compton, Chris
    Ismaila, Afisi S.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 : 231 - 245
  • [24] Adherence to umeclidinium/vilanterol versus inhaled corticosteroids/long-acting β2-agonist in patients with chronic obstructive pulmonary disease in England
    Czira, A.
    Requena, G.
    Banks, V
    Wood, R.
    Tritton, T.
    Castillo, C.
    Yeap, J.
    Wild, R.
    Compton, C.
    Duarte, M.
    Rothnie, K.
    Ismaila, A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [25] Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
    Fukuda, Nobuhiko
    Horita, Nobuyuki
    Kaneko, Ayami
    Goto, Atsushi
    Kaneko, Takeshi
    Ota, Erika
    Kew, Kayleigh M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (06):
  • [26] Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND) A Randomized Clinical Trial
    Martinez, Fernando J.
    Rabe, Klaus F.
    Sethi, Sanjay
    Pizzichini, Emilio
    Mclvor, Andrew
    Anzueto, Antonio
    Alagappan, Vijay K. T.
    Siddiqui, Shahid
    Rekeda, Ludmyla
    Miller, Christopher J.
    Zetterstrand, Sofia
    Reisner, Colin
    Rennard, Stephen I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (05) : 559 - 567
  • [27] Engineering of Crystalline Combination Inhalation Particles of a Long-Acting β2-agonist and a Corticosteroid
    Chonladda Pitchayajittipong
    Jagdeep Shur
    Robert Price
    Pharmaceutical Research, 2009, 26 : 2657 - 2666
  • [28] Engineering of Crystalline Combination Inhalation Particles of a Long-Acting β2-agonist and a Corticosteroid
    Pitchayajittipong, Chonladda
    Shur, Jagdeep
    Price, Robert
    PHARMACEUTICAL RESEARCH, 2009, 26 (12) : 2657 - 2666
  • [29] Combination therapy with a long-acting β2-agonist and an inhaled corticosteroid as initial maintenance treatment in asthma
    Lee, DKC
    Currie, GP
    Lipworth, BJ
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2005, 94 (03) : 410 - 411
  • [30] In vitro synergism of inhaled corticosteroid and long-acting β2-agonist is not translated clinically in vivo -: Reply
    Pace, E
    Gjomarkaj, M
    Gagliardo, R
    Melis, M
    La Grutta, S
    Ferraro, M
    Siena, L
    Bonsignore, G
    Bousquet, J
    Vignola, AM
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 115 (04) : 880 - 881
12345